Artivion (NYSE:AORT) Receives Buy Rating from Needham & Company LLC

Needham & Company LLC reissued their buy rating on shares of Artivion (NYSE:AORT) in a research report report published on Monday, MarketBeat.com reports. They currently have a $44.00 price objective on the stock.

Other equities research analysts have also issued research reports about the company. Weiss Ratings lowered Artivion from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, June 8th. LADENBURG THALM/SH SH upgraded Artivion from a “neutral” rating to a “buy” rating and set a $42.00 target price for the company in a report on Friday, April 10th. Canaccord Genuity Group reissued a “buy” rating and issued a $36.00 price target on shares of Artivion in a research note on Tuesday, June 16th. Citizens Jmp cut their price target on Artivion from $53.00 to $48.00 and set a “market outperform” rating on the stock in a report on Friday, May 8th. Finally, Wall Street Zen downgraded shares of Artivion from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $44.17.

Artivion Stock Performance

Shares of AORT opened at $25.44 on Monday. The company has a current ratio of 3.86, a quick ratio of 2.80 and a debt-to-equity ratio of 0.48. The firm’s fifty day simple moving average is $22.49 and its two-hundred day simple moving average is $32.79. Artivion has a 12 month low of $19.16 and a 12 month high of $48.25. The stock has a market capitalization of $1.23 billion, a P/E ratio of 106.00 and a beta of 1.26.

Insider Buying and Selling at Artivion

In other Artivion news, SVP Andrew M. Green sold 44,001 shares of the firm’s stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $20.70, for a total value of $910,820.70. Following the transaction, the senior vice president directly owned 60,259 shares of the company’s stock, valued at approximately $1,247,361.30. This trade represents a 42.20% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 6.30% of the company’s stock.

Institutional Investors Weigh In On Artivion

Institutional investors and hedge funds have recently made changes to their positions in the business. Caitong International Asset Management Co. Ltd acquired a new position in Artivion during the 3rd quarter valued at about $27,000. Rockefeller Capital Management L.P. raised its stake in shares of Artivion by 150.0% in the fourth quarter. Rockefeller Capital Management L.P. now owns 665 shares of the company’s stock worth $30,000 after purchasing an additional 399 shares during the last quarter. Larson Financial Group LLC raised its stake in shares of Artivion by 148.5% in the fourth quarter. Larson Financial Group LLC now owns 942 shares of the company’s stock worth $43,000 after purchasing an additional 563 shares during the last quarter. USA Financial Formulas lifted its holdings in shares of Artivion by 163.5% in the fourth quarter. USA Financial Formulas now owns 1,133 shares of the company’s stock valued at $52,000 after purchasing an additional 703 shares in the last quarter. Finally, Smartleaf Asset Management LLC lifted its holdings in shares of Artivion by 47.7% in the second quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock valued at $52,000 after purchasing an additional 538 shares in the last quarter. Institutional investors and hedge funds own 86.37% of the company’s stock.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.